Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The associated price target remains the same with $85.00.
Cory Jubinville, PhD’s rating is based on Tarsus Pharmaceuticals’ impressive financial performance and strategic growth initiatives. The company has consistently exceeded revenue expectations, with Q1 2025 marking the sixth consecutive quarter of surpassing consensus estimates. This success is largely attributed to the robust demand for their product, Xdemvy, which saw an 18% quarter-over-quarter growth in prescriptions.
Additionally, Tarsus is actively investing in its pipeline, with plans to initiate a Phase 2 study for ocular rosacea using their TP-04 formulation. This move highlights their commitment to expanding into new therapeutic areas and capitalizing on unmet medical needs. The company’s strategic initiatives and strong financial health, including a solid cash position, further support the Buy rating, as they are well-positioned for continued growth and innovation in the ophthalmic sector.
In another report released today, Guggenheim also maintained a Buy rating on the stock with a $84.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TARS in relation to earlier this year.